已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Targeted Therapies for Triple-Negative Breast Cancer

医学 奥拉帕尼 阿替唑单抗 乳腺癌 三阴性乳腺癌 肿瘤科 内科学 靶向治疗 癌症 艾瑞布林 PARP抑制剂 癌症研究 转移性乳腺癌 免疫疗法 彭布罗利珠单抗 生物 基因 聚ADP核糖聚合酶 生物化学 聚合酶
作者
Tomás G. Lyons
出处
期刊:Current Treatment Options in Oncology [Springer Science+Business Media]
卷期号:20 (11) 被引量:273
标识
DOI:10.1007/s11864-019-0682-x
摘要

Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer. TNBC is a heterogenous subtype of breast cancer that is beginning to be refined by its molecular characteristics and clinical response to a targeted therapeutic approach. Until recently the backbone of therapy against TNBC has been cytotoxic chemotherapy. However, the breast oncology community is now seeing encouraging clinical activity from molecularly targeted approaches to TNBC. Recently, we have seen 3 newly approved targeted therapies for TNBC, including the PARP inhibitors olaparib and talazoparib for germline BRCA mutation associated breast cancer (gBRCAm-BC) and most recently the checkpoint inhibitor, atezolizumab in combination with nab-paclitaxel for programmed death-ligand 1 (PD-L1+) advanced TNBC. Improved biomarkers are needed to inform better patient selection for treatment with checkpoint inhibition. Higher response rates are seen when checkpoint inhibitors are combined with chemotherapy in the first-line setting and the use of these agents at an earlier stage of the disease does show promise. Antibody-drug conjugates are generating much excitement and may allow re-examination of prior cytotoxics that failed in development due to toxicity. Tumor sequencing is identifying potential molecular targets and ongoing studies are evaluating novel small molecule agents in this field such as AKT inhibition and many others. The treatment paradigm of chemotherapy as “one size fits all” approach for management of TNBC is changing based on molecular subtyping. Soon, the term TNBC may no longer be appropriate, as this heterogenous subtype of breast cancer is further refined by its molecular characteristics and clinical response to a targeted therapeutic approach.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bkagyin应助叶某还得学采纳,获得10
5秒前
9秒前
12秒前
aaaaarfv发布了新的文献求助10
13秒前
田様应助风赴云扑采纳,获得10
16秒前
CodeCraft应助科研通管家采纳,获得10
16秒前
所所应助科研通管家采纳,获得10
16秒前
搜集达人应助科研通管家采纳,获得10
16秒前
CipherSage应助科研通管家采纳,获得10
16秒前
酷波er应助科研通管家采纳,获得10
16秒前
小蘑菇应助科研通管家采纳,获得10
17秒前
小蘑菇应助科研通管家采纳,获得10
17秒前
Keria发布了新的文献求助10
17秒前
18秒前
晗晗子关注了科研通微信公众号
22秒前
kyrie发布了新的文献求助10
24秒前
慕青应助H_C采纳,获得10
26秒前
逍遥呱呱完成签到 ,获得积分10
26秒前
希望天下0贩的0应助水水采纳,获得10
35秒前
Keria完成签到,获得积分10
37秒前
39秒前
lighting完成签到 ,获得积分10
41秒前
GTRK完成签到 ,获得积分10
41秒前
困困发布了新的文献求助10
45秒前
水水完成签到,获得积分10
45秒前
48秒前
49秒前
53秒前
水水发布了新的文献求助10
54秒前
黄卡卡完成签到,获得积分10
55秒前
jdwxiang123发布了新的文献求助10
56秒前
王晓静完成签到 ,获得积分10
57秒前
吃的饭广泛举报安详世开求助涉嫌违规
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
噗噗完成签到,获得积分10
1分钟前
CHSLN完成签到 ,获得积分10
1分钟前
胡茶茶完成签到 ,获得积分10
1分钟前
高分求助中
Mass producing individuality 600
Разработка метода ускоренного контроля качества электрохромных устройств 500
A Combined Chronic Toxicity and Carcinogenicity Study of ε-Polylysine in the Rat 400
Advances in Underwater Acoustics, Structural Acoustics, and Computational Methodologies 300
Effect of deresuscitation management vs. usual care on ventilator-free days in patients with abdominal septic shock 200
Erectile dysfunction From bench to bedside 200
Advanced Introduction to Behavioral Law and Economics 200
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3824880
求助须知:如何正确求助?哪些是违规求助? 3367298
关于积分的说明 10444910
捐赠科研通 3086493
什么是DOI,文献DOI怎么找? 1698084
邀请新用户注册赠送积分活动 816632
科研通“疑难数据库(出版商)”最低求助积分说明 769848